Angiotensin II (ANG II) contracts umbilical arteries and has been hypothesized to regulate fetal blood pressure primarily by altering umbilical vascular resistance. To determine whether systemic arteries in term fetal sheep are sensitive to ANG II, isometric contraction of endothelium-intact isolated fetal renal, mesenteric, and umbilical arteries in response to ANG II was studied. ANG II (10 Ϫ7 M) elicited contractile responses in all three vessels (43 Ϯ 8%, 99 Ϯ 21%, and 105 Ϯ 5% of the maximal response seen with 90 mM KCl for renal, mesenteric, and umbilical arteries, respectively). The time course of the contractile responses differed among the vessels: renal and mesenteric arteries exhibited rapid transient contraction followed by relaxation, whereas umbilical artery displayed a more slowly developing but sustained contraction (1 Ϯ 0%, 3 Ϯ 1%,and 93 Ϯ 4% of maximal contractile response at 5 min, for renal, mesenteric, and umbilical arteries, respectively). The AT 1 receptor antagonist, losartan (10 Ϫ6 M), abolished contractile responses in renal and mesenteric arteries but only slowed the contraction in umbilical artery in response to ANG II and had no effect on maximal tension. AT 2 receptor blockade (PD 123319, 10 Ϫ7 M) had no significant effect on the response to ANG II in any vessel. Indomethacin (10 Ϫ6 M) significantly potentiated contraction to ANG II in renal and mesenteric but not umbilical arteries.
Angiotensin II (ANG II) contracts umbilical arteries and has been hypothesized to regulate fetal blood pressure primarily by altering umbilical vascular resistance. To determine whether systemic arteries in term fetal sheep are sensitive to ANG II, isometric contraction of endothelium-intact isolated fetal renal, mesenteric, and umbilical arteries in response to ANG II was studied. ANG II (10 Ϫ7 M) elicited contractile responses in all three vessels (43 Ϯ 8%, 99 Ϯ 21%, and 105 Ϯ 5% of the maximal response seen with 90 mM KCl for renal, mesenteric, and umbilical arteries, respectively). The time course of the contractile responses differed among the vessels: renal and mesenteric arteries exhibited rapid transient contraction followed by relaxation, whereas umbilical artery displayed a more slowly developing but sustained contraction (1 Ϯ 0%, 3 Ϯ 1%,and 93 Ϯ 4% of maximal contractile response at 5 min, for renal, mesenteric, and umbilical arteries, respectively). The AT 1 receptor antagonist, losartan (10 Ϫ6 M), abolished contractile responses in renal and mesenteric arteries but only slowed the contraction in umbilical artery in response to ANG II and had no effect on maximal tension. AT 2 receptor blockade (PD 123319, 10 Ϫ7 M) had no significant effect on the response to ANG II in any vessel. Indomethacin (10 Ϫ6 M) significantly potentiated contraction to ANG II in renal and mesenteric but not umbilical arteries.
Northern and Western blot analyses demonstrated the presence of AT 1 mRNA and protein in all three vessels. Immunostaining for the AT 1 receptor was present in endothelium and the tunica media. These findings demonstrate the AT 1 receptor is present and functionally active in fetal systemic arteries and are consistent with previous findings that the umbilical circulation displays a greater responsiveness to ANG II than the systemic vasculature. The renin-angiotensin system is active in the fetus and newborn and is an important modulator of circulatory function (1, 2) . The effects of ANG II are mediated by two distinct receptors, classified as type 1 (AT 1 ) and type 2 (AT 2 ) on the basis of selective antagonism by peptide and nonpeptide ligands (3, 4) . The tissue distribution and expression of these receptors are developmentally regulated, changing throughout fetal and early postnatal life. In general, AT 2 receptor expression is high in embryonic and fetal tissues, decreasing late in development and with postnatal maturation, whereas AT 1 receptors appear later in fetal life with expression greatest in tissues regulating cardiovascular and fluid and electrolyte homeostasis (5) (6) (7) (8) . Most of the known physiologic responses to ANG II are mediated by the AT 1 receptor. Far less is known about the role of the AT 2 receptor, although there are reasons to believe this receptor exerts antigrowth, antihypertrophic, proapoptotic, and vasodepressor effects (9) . The sites and mechanisms by which ANG II regulates arterial pressure in the fetus are not clear. The umbilicalplacental vascular bed is an important regulator of fetal total peripheral vascular resistance and may be the primary site at which circulating ANG II regulates fetal arterial pressure. The umbilical circulation is far more sensitive to infused ANG II than the fetal systemic vasculature as determined by changes in blood flow and vascular resistance (10 -12) . Recent studies by Kaiser et al. (12) and Cox and Rosenfeld (13) suggest that differences between umbilical and fetal systemic vascular responses to ANG II are related to differences in ANG II receptor subtype expression, AT 1 receptors predominating in umbilical arteries and fetal systemic arteries expressing only AT 2 receptors.
If ANG II regulates fetal blood pressure by altering umbilical vascular resistance, how then does ANG II regulate blood pressure immediately after birth? In mature animals, extensive interactions between the renin-angiotensin system and the autonomic nervous system in the maintenance of cardiovascular homeostasis are known to exist. For example, ANG II has been shown to stimulate sympathetic outflow, facilitate sympathetic neurotransmission, and modulate baroreceptor reflexes (14, 15) . In a previous study, we demonstrated in newborn lambs that endogenous circulating and central ANG II acts to maintain arterial pressure and exerts a tonic effect on baroreflex control of heart rate and renal sympathetic nerve activity (16) . However, the direct effects of ANG II on the systemic vasculature early in development have not been evaluated in detail. The present study was designed to determine whether renal and mesenteric arteries of term fetal sheep are sensitive to ANG II, and to compare the contractile responses of these vessels with those of the umbilical artery.
METHODS
Tissue collection. All procedures were performed within the regulations of the Animal Welfare Act and the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of Iowa Animal Care and Use Committee. Time-dated pregnant ewes at 134 -140 d gestation (term, 145 d) were obtained from a local source. Undisturbed twins of fetal sheep used for unrelated studies served as the tissue source. Because the unrelated protocol required delivery by cesarean section, pregnant ewes were given anesthetic induction with 12 mg/kg of thiopental sodium, (Abbott Laboratories, North Chicago, IL, U.S.A.), intubated, and ventilated with room air. Low spinal anesthesia (1% lidocaine, 10 mL) was administered to the ewe, after which the lamb was delivered by cesarean section. Fetuses were euthanized with i.v. pentobarbital sodium (50 mg/kg), and the renal, first-generation mesenteric, and external umbilical arteries were collected. Arterial segments, from which residual blood was expressed and fat and connective tissue were removed, were quickly placed in either ice-cold calciumfree PSS, 4% paraformaldehyde, or snap-frozen in liquid nitrogen.
Isolated vessel contractile responses. Arterial segments were cleaned of adherent connective tissue and cut into 3-to 5-mm rings. The endothelium was left intact, and the rings were mounted in individual 18-mL isolated organ chambers and connected to an isometric force transducer by 32-gauge stainless steel wire. Contractile responses were recorded with an eight-channel MacLab 8E (ADInstruments Pty Ltd. Castle Hill, NSW, Australia) and stored on a Power Macintosh 7300 computer (Apple Computers Inc., Cupertino, CA, U.S.A.). The length-tension relationship was defined experimentally in each vessel using the response to 90 mM KCl at varying degrees of passive stretch. Passive stretch was set at 90% of the tension required to obtain peak responses to KCl (1.5 g for renal and mesenteric arteries, 3.0 g for the umbilical artery), and rings were allowed to equilibrate in PSS at 37°C for 120 min before the start of experimentation. PSS was aerated with a mixture of 95% O 2 /5% CO 2 ; the composition was as follows (in mM): 130 NaCl, 4. Endothelium-intact isolated vessels underwent testing according to one of the following three protocols. Individual vessel rings were used for only one protocol. From any single fetus, renal, mesenteric, and umbilical arteries were studied in duplicate (two vessel rings from each artery) and simultaneously according to a specific protocol as outlined below. The duplicate responses for each vessel type were averaged to yield a specific data point for that particular vessel. Protocol 1. These studies determined the contractile response to ANG II. At the beginning of each experiment, a contraction to 90 mM KCl was recorded by adding KCl directly to the buffer from a 1 M stock solution. The bath was washed three times with PSS for a 10-min period, then the vessels were allowed to equilibrate again for 20 min before addition of ANG II (10 Ϫ7 M). This concentration has previously been demonstrated in a number of published doseresponse studies to be near the effective concentration producing 50% of the maximal response for umbilical artery responses to ANG II (17, 18) . The sequence was repeated three times to evaluate the development of tachyphylaxis in the three vessel types.
Protocol 2. To determine the ANG II receptor type mediating vasoconstriction, a different set of vessels was first contracted with KCl. After washing three times with PSS, vessels were then incubated for 20 min in the presence of the AT 1 receptor antagonist, losartan (10 Ϫ6 M), the AT 2 receptor antagonist PD 123319 (10 Ϫ6 M), or vehicle (PSS) before the contractile response to ANG II (10 Ϫ7 M) was measured. The umbilical artery contractile responses to ANG II in the presence of a higher concentration of losartan (10 Ϫ5 M) and the nonselective ANG II receptor antagonist saralasin (10 Ϫ5 M) were also measured.
Protocol 3. These studies determined the role of prostaglandins in regulating the contractile responses to ANG II. Arterial segments were first contracted with ANG II (10 Ϫ7 M), washed three times with PSS, then incubated in indomethacin (10 Ϫ8 M to 10 Ϫ6 M) or vehicle for 20 min before ANG II was again added to the bath. Indomethacin was prepared as a stock solution in DMSO. To determine whether prostaglandin production participates in the development of tachyphylaxis, we elected to measure the ANG II response after incubation with indomethacin during the second exposure to ANG II. Therefore, the measured responses are presented as the percent of the contractile response seen in vehicle (DMSO)-treated vessels with the second administration of ANG II.
RNA extraction and Northern blot analysis. Cellular RNA was isolated using Tri-Reagent (Molecular Research Center, Cincinnati, OH, U.S.A.). RNA was quantified spectrophotometrically by absorbance at 260 nm. RNA samples were stored as an ethanol precipitate at Ϫ70°C until further analysis. An ovine-specific AT 1 receptor 32 P-labeled antisense RNA probe previously used and described by our group was used to detect the presence of AT 1 mRNA (6). We also attempted but were unsuccessful in detecting AT 2 mRNA by Northern blot analysis, likely because of technical difficulties. An 18S rRNA probe prepared from an 18S cDNA clone corresponding to an 82-bp fragment of a highly conserved region of human 18S rRNA (Ambion Inc., Austin, TX, U.S.A.) was used to determine variability in loading and transfer of RNA.
Aliquots of 10 g of RNA as measured by absorbance at 260 nm were fractionated by 1% formaldehyde-agarose gel elec-827 FETAL VASCULAR RESPONSES TO ANGIOTENSIN II trophoresis. After electrophoresis, RNA was transferred to a 0.45-mm Nytran filter. The filters were prehybridized for 1 h at 60°C in a solution of 50% deionized formamide, 5ϫ SSPE (875 mM sodium chloride, 50 mM sodium phosphate, 5 mM EDTA), 5ϫ Denhardt's reagent, 0.5% SDS, and 200 g/mL denatured sheared salmon sperm DNA. Hybridization of filters was performed with fresh hybridization buffer solution containing 2 ϫ 10 6 counts/min/mL of the appropriate radiolabeled probe. The hybridization reaction was performed at 60°C for 12-18 h. Filters were washed with three low-stringency washes (1ϫ SSPE, 0.5% SDS) at 68°C and a high-stringency wash (0.1ϫ SSPE, 0.5%SDS) at 65°C and exposed to Kodak XAR film at Ϫ70°C.
Immunoblotting. Western blot analysis for AT 1 and AT 2 were performed as previously described (19) . Fetal renal cortex (from 140 d gestation, term 145 d) and adult adrenal were used as control tissues for AT 1 and AT 2 protein. The adult adrenal medulla of large mammals (human, bovine, ovine) expresses high levels of AT 1 but not AT 2 receptor. Both AT 1 and AT 2 receptors are present in fetal kidneys, although AT 2 expression decreased significantly after completion of nephrogenesis (after 130 -135 d gestation) (20 -22) . Protein concentrations were determined by the method of Lowry, as modified by Peterson (23) . The AT 1 receptor-specific polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) was raised in rabbits against an epitope corresponding to amino acids 306 -359 of the human AT 1 receptor and has previously been used for the detection of the ovine AT 1 receptor (21, 24) . The AT 2 receptor-specific polyclonal antibody (Santa Cruz Biotechnology) was raised in rabbits against an epitope corresponding to amino acids 221-363 mapping the carboxy terminus of the human AT 2 receptor and has been shown to be mouse, rat, and human reactive. Nitrocellulose blots (20 g of protein per lane) were incubated with the primary antibody at a 1:2000 (AT 1 ) or 1:6000 (AT 2 ) dilution in 1% gelatin/TTBS (Tween-zo-Tris buffered saline) for 2 h at room temperature. Blots were rinsed, washed, and then incubated with a 1:8000 dilution of goat anti-rabbit horseradish peroxidase-conjugated antibody (Sigma Chemical Co., St. Louis, MO, U.S.A.) in 1% gelatin/TTBS at room temperature for 1 h. Binding of the secondary antibody was detected using a chemiluminescent system consisting of horseradish peroxidase-hydrogen peroxide oxidation of luminol (ECL, Amersham, Arlington Heights, IL, U.S.A.). Blots were then exposed to Fuji RX x-ray film for 1 min.
Immunohistochemistry. Isolated vessels were fixed in formalin (10%) and embedded in paraffin, and sections were mounted on glass slides. Sections were deparaffinized in xylene and hydrated in an ethanol-PBS series. After a 5-min PBS rinse, sections were incubated in H 2 O 2 (3%) in methanol for 30 min before rinsing with PBS (ϫ2) and blocking with BSA (1% in PBS). Sections were incubated with primary antibody, either rabbit anti-AT 1 , 1:100 dilution or rabbit anti-AT 2 , 1:100 dilution overnight at 4°C. The sections were then rinsed two times for 10 min per rinse in PBS and stained using a Vectastain Elite kit (Vector Laboratories, Inc., Burlingame, CA, U.S.A.). The tissue sections were incubated for 30 min in biotinylated secondary antibody, rinsed two times in PBS, and then incubated for 45 min in avidin-peroxidase reagent. After rinsing two times in PBS, sections were incubated in diaminobenzidine for 1-3 min. Sections were rinsed in PBS for 5 min, rinsed quickly in distilled water, counterstained with hematoxylin for 1 min, dehydrated, and then mounted with glass coverslips. Incubation with secondary antibody alone was performed for each vessel type to serve as controls.
Data analysis. One-way ANOVA was performed for comparisons among groups. When F ratios were significant, Newman-Keuls test was applied to identify which groups were significantly different. Statistical difference was defined as p Ͻ 0.05. Values are presented as mean Ϯ SEM.
RESULTS
Contractile responses to ANG II were present in all three vessel types, although the character of the responses differed. The force recording shown in Figure 1 demonstrates that both the renal and mesenteric arteries exhibited rapid, transient contractions to ANG II followed by relaxation, whereas the umbilical artery displayed a slower yet far more sustained contraction. The renal artery contractile response elicited by ANG II (relative to the responses to 90 mM KCl) was less (p Ͻ 0.05) than that seen in mesenteric or umbilical arteries (Fig.  2 , n ϭ 4 for each vessel type). However, the duration of the contractile response was significantly greater in the umbilical compared with the renal and mesenteric arteries. Five minutes after addition of ANG II to the bath buffer, umbilical arteries were still maximally contracted. On the other hand, renal and mesenteric vessels had relaxed to near resting levels by this time. Tachyphylaxis also developed in all three vessels, the extent being greater in renal compared with mesenteric and umbilical arteries (Fig. 3 , n ϭ 4 for each vessel type). To determine the ANG II receptor subtype mediating the contractile responses, 20-min incubations in either losartan (10 Ϫ6 M), PD 123319 (10 Ϫ6 M), or vehicle were performed before exposure to ANG II (Fig. 2 , n ϭ 4 for each vessel type). Losartan significantly inhibited ANG II-induced contractions in renal and mesenteric arteries but at this concentration had no effect on the umbilical artery response. At a concentration of 10 Ϫ5 M, 100-fold greater than the concentration of ANG II, losartan attenuated but did not completely inhibit the contractile response in umbilical artery (Fig. 4) . Contraction to ANG II was completely inhibited by saralasin (10 Ϫ5 M). No significant effects of PD 123319 on the contractile responses to ANG II were seen in any vessel (Fig. 2) .
ANG II responses after exposure to varying concentrations of indomethacin were measured to determine the role of prostaglandins in regulating contractility (Fig. 5) . Indomethacin (10 Ϫ6 M) potentiated the peak contraction to ANG II by Ͼ100% in both renal and mesenteric arteries (p Ͻ 0.05). A slight but nonsignificant increase in the ANG II response was seen in the umbilical artery. No significant effects of indomethacin at concentrations of 10 Ϫ7 or 10 Ϫ8 M were detected. Indomethacin did not appear to alter the time course of the responses to ANG II.
Northern and Western blotting performed on vessels from four different fetuses consistently demonstrated the presence of AT 1 mRNA and protein in all three arteries (Figs. 6 and 7) . AT 1 receptor mRNA was detected by Northern blot analysis at the expected size of 2.4 kb. The immunoblots probed with the AT 1 receptor antibody showed bands of the expected size in the renal, mesenteric, and umbilical arteries as well as in term-gestation fetal kidney cortex and adult adrenal, with the major band at 67 kD, as previously reported by Marrero et al. (25) . Western blot analysis also demonstrated that AT 2 receptor protein was present in all arterial segments, with a major band at approximately 78 kD. The primary band in fetal kidney was present at 44 kD, as previous reported in rat heart and kidney (26, 27) . AT 2 receptor protein was barely detectable in adult adrenal extracts (Fig. 7) . 
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Immunostaining for AT 1 and AT 2 receptors was performed to localize the receptors within the arteries. Positive staining for the AT 1 receptor protein is seen in all three vessels, most prominently in the outer one third of the tunica media (Fig. 8) . Interestingly, staining for AT 1 appears more homogeneous in vascular smooth muscle of mesenteric artery than in either renal or mesenteric arteries. AT 2 receptors also appeared localized to the outer portion of the media in renal and mesenteric arteries. AT 2 staining appeared less intense in umbilical artery compared with systemic arteries.
DISCUSSION
The manner by which the renin-angiotensin system participates in fetal cardiovascular homeostasis is not entirely clear; however, several lines of evidence suggest that regulation of umbilical resistance may be an important mechanism by which ANG II modulates fetal arterial pressure. The umbilicalplacental vascular bed, which receives approximately 40% of the combined ventricular output, is believed to contribute substantially to total peripheral resistance in the fetus (28) . Both in vitro and in vivo studies have demonstrated that the umbilical circulation is extremely sensitive to ANG II (11, 12, 18, 29, 30) . Far less is known, however, regarding the functional responses of fetal systemic vessels to ANG II. We have used a variety of methods to gather data regarding the presence and function of ANG II receptors in fetal systemic arteries and have compared these findings to those seen in the external umbilical artery. Our findings demonstrate that AT 1 mRNA and protein are present in isolated fetal ovine renal, mesenteric, and umbilical arteries and that this receptor mediates contraction in response to exogenous ANG II in these vessels. There were, however, inherent differences in the contractile responses of the vessels as the renal and mesenteric arteries exhibited rapid, transient contractions to ANG II followed by relaxation, whereas umbilical arteries displayed a slower and more sustained contraction. Finally, incubation with the cyclooxygenase inhibitor indomethacin significantly enhanced the magnitude of the ANG II-induced contractile response of renal and mesenteric arteries, having little effect on the response of the umbilical artery.
Recently, Cox and Rosenfeld (13) reported that the AT 2 receptor appeared to be the predominant ANG II receptor in fetal systemic conduit vessels. In these studies, competitive inhibition binding assays performed in plasma membranes of fetal aorta and carotid and mesenteric arterial vascular smooth muscle failed to demonstrate the presence of a population of AT 1 receptors, although AT 2 receptors were present. On the other hand, AT 1 receptors were present in the umbilical artery and its primary tributaries, but not subsequent branches. In contrast, our findings suggest that AT 1 receptors are present in fetal sheep renal and mesenteric arteries. Using Northern blot hybridization, we demonstrated the presence of AT 1 mRNA in Western blot analysis for the AT 1 and AT 2 proteins in ovine fetal renal, mesenteric, and umbilical arteries, fetal kidney (cortex), and adult adrenal homogenates (20 g loaded per lane). For this figure, tissue samples from two different animals were analyzed. AT 1 receptor protein was detected in all three vessels with major bands at approzimately 67 and 40 kD. AT 2 receptor protein was also detected in all three vessels and to a lesser extent in fetal kidney (cortex) and adult adrenal. 830 renal and mesenteric arteries, as well as in umbilical artery. Immunoblotting as well as immunohistochemistry verified the presence of AT 1 receptor protein in these vessels. The Western blots demonstrated several bands for the AT 1 receptor in the fetal arteries, similar to that previously found by us and others in fetal ovine tissues (19, 22) . The presence of multiple bands may be related to various degrees of protein glycosylation, protein degradation, and experimental conditions. For instance, using Western blot analysis for the AT 1 receptor in ovine tissues, Wintour and colleagues (22) demonstrated that the band size and numbers differed depending on the source of primary antibody.
In addition to demonstrating the presence of AT 1 receptors in fetal systemic and umbilical arteries, we showed that AT 1 receptors were functional and mediated contractile responses to ANG II. ANG II-induced contractions in fetal renal and mesenteric arteries were nearly completely abolished by blockade of the AT 1 receptor with losartan, a finding consistent with the generally accepted function of this receptor. Interestingly, the concentration of losartan that blocked ANG II-induced contraction in renal and mesenteric arteries had no effect on umbilical artery contraction. At a 10-fold higher concentration (10 Ϫ5 M), losartan inhibited approximately 70% of the umbilical artery contraction to ANG II. Reasons for this difference in antagonist sensitivity may be related to differences in AT 1 receptor number or affinity in different tissues. It also raises the possibility that contraction of the umbilical artery is mediated by a non-AT 1 or -AT 2 type receptor, which is blocked nonspecifically by losartan at high concentrations and by the ANG II analog saralasin.
Using immunoblotting and immunohistochemistry techniques, we were able to demonstrate expression of AT 2 receptors in renal and mesenteric arteries, consistent with the binding studies of Cox and Rosenfeld (13) . However, we also localized AT 2 receptors to the umbilical artery by immunoblotting, unlike the findings reported by these authors. Not surprisingly, blockade of the AT 2 receptors with PD 123319 had no demonstrable effect on ANG II-induced contraction in any vessel type. Although the functions of AT 2 receptors are poorly understood, AT 2 receptors have previously been re- Bottom, control studies performed using secondary antibody alone. Brown staining depicts positive signal. A, B, and C, immunostaining for AT 1 receptor protein in renal, mesenteric, and umbilical arteries, respectively. Magnification ϫ250 for renal and mesenteric arteries, ϫ100 for umbilical artery. D, E, and F, immunostaining for AT 2 receptor protein in renal, mesenteric, and umbilical arteries, respectively. Magnification ϫ250 for renal and mesenteric arteries, ϫ100 for umbilical artery. G, H, and I, staining with secondary antibody alone in renal, mesenteric, and umbilical arteries, respectively. Magnification ϫ250 for renal and mesenteric arteries, ϫ100 for umbilical artery.
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ported to cause vasodilation in preglomerular afferent arteriole (31) . Whether a similar effect occurs in fetal systemic vessels, which appear to express high concentrations of AT 2 receptors, will require further studies using precontracted vessels.
We found dramatic differences in the character of the contractile response of the umbilical artery to KCl and ANG II compared with those seen in the renal or mesenteric artery. Although the initial vasoconstrictor response was of similar magnitude in the mesenteric and umbilical arteries (when expressed as percent of the response to 90 mM KCl), both were significantly greater than the renal artery response. Contraction was slower in onset and far more sustained in the umbilical artery than in the other vessels. Five minutes after addition of ANG II, umbilical artery contraction was still at its maximal response, whereas renal and mesenteric arteries had undergone significant relaxation. Interestingly, Adamson et al. (11) found in fetal sheep that the increase in arterial pressure associated with administration of ANG II occurs before an increase in placental vascular resistance, and they speculated that placental constriction probably contributes more to the maintenance than to the onset of the pressor response. Our data support these conclusions and suggest that vasoconstriction of fetal systemic arteries is responsible for the initial ANG II-induced increase in arterial pressure, whereas the slower but sustained contraction of the umbilical vasculature contributes to sustaining the hypertensive response.
The different characteristics of the contraction responses in renal and mesenteric arteries compared with umbilical artery are intriguing and suggest fundamental differences exist among the vessels. Structural differences among the vessels are one obvious factor that could contribute to the observed differences in responses of the vessels. Because the umbilical artery is a much thicker-walled vessel than the renal or mesenteric artery, the ability of ANG II to reach ANG II receptors may be relatively delayed. Furthermore, Arens et al. (32) found vascular smooth muscle from fetal femoral arteries and aorta to be biochemically and functionally immature compared with umbilical and adult arteries. Specifically, actin and total myosin content were greater in the umbilical artery, and myosin heavy chain (MHC) isoform composition also differed. These differences in contractile protein composition could alter the contractile capacities of the different vessels. However, both renal and mesenteric arteries underwent stable, sustained contractile responses to KCl.
ANG II is known to induce the release of arachidonic acid metabolites, and cyclooxygenase and lipoxygenase inhibitors have been shown to alter ANG II-mediated contractile responses in umbilical and systemic arteries (33) (34) (35) . We therefore postulated that generation of vasoactive prostanoids might contribute to the different types of contractile responses among the arteries studied. At the highest concentration tested, indomethacin (10 Ϫ6 M) significantly potentiated the responses to ANG II in renal and mesenteric, but not umbilical, arteries. The transient nature of the ANG II-induced responses was not altered by indomethacin. These findings suggest differences in basal production or ANG II-induced release of vasoactive arachidonic acid metabolites may contribute more to regulating fetal systemic than umbilical artery responsiveness to ANG II.
In vivo, prostacyclin infusion has no effect on ovine umbilicalplacental resistance, possibly because of the lack of functional receptors (36, 37) . Yoshimura et al. (38, 39) have demonstrated that basal prostaglandin production is greater in mesenteric artery than placental vessels, although ANG II increased placental but not mesenteric artery production of prostaglandin E and prostacyclin derivatives. In rats, participation of prostanoids in regulating the vascular response to ANG II is also dependent on developmental stage and blood vessel type (35) . Thus, regional differences in the balance between vasodilating and vasoconstricting prostaglandins may directly affect vascular tone in these fetal vessels. Finally, indomethacin, at high concentrations, may directly inhibit prostacyclin-mediated vasodilation and thereby potentiate vasoconstrictive effects of ANG II independent of changes in prostaglandin synthesis (40) .
The mechanisms by which ANG II modulates cardiovascular function and blood pressure during fetal life and immediately after birth remain to be fully elucidated. We have previously shown in newborn lambs that both systemic and intracerebroventricular infusion of losartan decreases arterial pressure and alters efferent sympathetic activity, suggesting involvement of peripheral and central AT 1 receptors in neural control of circulatory function (16) . The finding of a sustained contractile response of the umbilical artery to ANG II is consistent with previous findings that the umbilical artery displays a greater responsiveness to ANG II than the fetal systemic vasculature and supports the hypothesis that ANG II regulates fetal blood pressure by modulating the umbilicalplacental vascular bed. The decreased responsiveness of systemic arteries to ANG II may be related to ANG II-stimulated release of vasodilating prostaglandins or paracrine release of other vasoactive substances. Although our results demonstrate that the AT 1 receptor is present and functionally active in large systemic arteries of term fetal sheep, these findings may not be representative of responses of the whole vascular bed. Additional studies of resistance vessels are needed to determine whether a direct effect of ANG II on peripheral vascular AT 1 receptors contributes to modulation of arterial pressure after the transition from fetal to newborn life, when the umbilical circulation no longer contributes to total peripheral resistance.
